Pages that link to "Q34012421"
Jump to navigation
Jump to search
The following pages link to Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (Q34012421):
Displaying 50 items.
- Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups (Q21284803) (← links)
- Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome (Q24185813) (← links)
- Warfarin initiation nomograms for venous thromboembolism (Q24186324) (← links)
- Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients (Q24186523) (← links)
- Anticoagulation for people with cancer and central venous catheters (Q24193103) (← links)
- Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation (Q24194116) (← links)
- Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Q24194904) (← links)
- Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation (Q24194926) (← links)
- Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (Q24197472) (← links)
- Warfarin initiation nomograms for venous thromboembolism (Q24201274) (← links)
- Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (Q24201769) (← links)
- Prothrombin complex concentrate for perioperative reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients requiring acute surgical intervention (Q24202561) (← links)
- Anticoagulation for patients with cancer and central venous catheters (Q24235260) (← links)
- Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation (Q24235785) (← links)
- Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation (Q24236595) (← links)
- Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer (Q24236620) (← links)
- Anticoagulation for patients with cancer and central venous catheters (Q24236648) (← links)
- Assessing bleeding risk in patients taking anticoagulants (Q24619070) (← links)
- Venous Thromboembolic Disease (Q24631121) (← links)
- Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (Q24632951) (← links)
- Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians (Q26746917) (← links)
- Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review (Q26768639) (← links)
- Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions (Q26782931) (← links)
- Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities (Q26787046) (← links)
- Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? (Q26823542) (← links)
- Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice (Q26825230) (← links)
- Reversal of oral anticoagulation (Q26827835) (← links)
- Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis (Q27002899) (← links)
- Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy (Q27003406) (← links)
- Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon (Q27006860) (← links)
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing (Q27008360) (← links)
- Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance (Q27008491) (← links)
- Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation (Q27011524) (← links)
- Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety (Q27025527) (← links)
- Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. (Q27334876) (← links)
- Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention (Q28069809) (← links)
- The current approach of atrial fibrillation management (Q28076171) (← links)
- Pharmacology of anticoagulants used in the treatment of venous thromboembolism (Q28078967) (← links)
- Dabigatran etexilate: A novel oral direct thrombin inhibitor (Q28244905) (← links)
- Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor (Q28250157) (← links)
- Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial (Q28254407) (← links)
- Potential interaction between MonaVie Active and Warfarin (Q28270028) (← links)
- An update on recent patents on thrombin inhibitors (2010 - 2013) (Q28299898) (← links)
- Needs and barriers to improve the collaboration in oral anticoagulant therapy: a qualitative study (Q28396127) (← links)
- Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation (Q28477868) (← links)
- An anticoagulation therapy elective for third-year pharmacy students (Q30227404) (← links)
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial (Q30909780) (← links)
- A role for pharmacists in community-based post-discharge warfarin management: protocol for the 'the role of community pharmacy in post hospital management of patients initiated on warfarin' study (Q30996878) (← links)
- Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation (Q31042226) (← links)
- Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases (Q33381801) (← links)